Switch theme
Sign up to access all valuation multiples
Svas Biosana SpA operates in the production and distribution of medical device.
1972
n/a
LTM Revenue $143M
LTM EBITDA $18.2M
$107M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Svas Biosana has a last 12-month revenue (LTM) of $143M and a last 12-month EBITDA of $18.2M.
In the most recent fiscal year, Svas Biosana achieved revenue of $137M and an EBITDA of $17.5M.
Svas Biosana expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Svas Biosana valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $143M | XXX | $137M | XXX | XXX | XXX |
| Gross Profit | $123M | XXX | $34.1M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 25% | XXX | XXX | XXX |
| EBITDA | $18.2M | XXX | $17.5M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $11.9M | XXX | $10.9M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $7.3M | XXX | $5.8M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $34.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Svas Biosana's stock price is EUR 8 (or $9).
Svas Biosana has current market cap of EUR 43.7M (or $49.1M), and EV of EUR 95.4M (or $107M).
See Svas Biosana trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $107M | $49.1M | XXX | XXX | XXX | XXX | $1.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Svas Biosana has market cap of $49.1M and EV of $107M.
Svas Biosana's trades at 0.8x EV/Revenue multiple, and 6.1x EV/EBITDA.
Equity research analysts estimate Svas Biosana's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Svas Biosana has a P/E ratio of 6.7x.
See valuation multiples for Svas Biosana and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $49.1M | XXX | $49.1M | XXX | XXX | XXX |
| EV (current) | $107M | XXX | $107M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 5.9x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBIT | 9.0x | XXX | 9.8x | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.7x | XXX | 8.5x | XXX | XXX | XXX |
| EV/FCF | 16.0x | XXX | -62.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSvas Biosana's last 12 month revenue growth is 10%
Svas Biosana's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Svas Biosana's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Svas Biosana's rule of X is 38% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Svas Biosana and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 25% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Svas Biosana acquired XXX companies to date.
Last acquisition by Svas Biosana was XXXXXXXX, XXXXX XXXXX XXXXXX . Svas Biosana acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Svas Biosana founded? | Svas Biosana was founded in 1972. |
| Where is Svas Biosana headquartered? | Svas Biosana is headquartered in Italy. |
| Is Svas Biosana publicy listed? | Yes, Svas Biosana is a public company listed on MIL. |
| What is the stock symbol of Svas Biosana? | Svas Biosana trades under SVS ticker. |
| When did Svas Biosana go public? | Svas Biosana went public in 2021. |
| Who are competitors of Svas Biosana? | Similar companies to Svas Biosana include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Svas Biosana? | Svas Biosana's current market cap is $49.1M |
| What is the current revenue of Svas Biosana? | Svas Biosana's last 12 months revenue is $143M. |
| What is the current revenue growth of Svas Biosana? | Svas Biosana revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Svas Biosana? | Current revenue multiple of Svas Biosana is 0.8x. |
| Is Svas Biosana profitable? | Yes, Svas Biosana is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Svas Biosana? | Svas Biosana's last 12 months EBITDA is $18.2M. |
| What is Svas Biosana's EBITDA margin? | Svas Biosana's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Svas Biosana? | Current EBITDA multiple of Svas Biosana is 5.9x. |
| What is the current FCF of Svas Biosana? | Svas Biosana's last 12 months FCF is $6.7M. |
| What is Svas Biosana's FCF margin? | Svas Biosana's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Svas Biosana? | Current FCF multiple of Svas Biosana is 16.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
